Featured Education

p24036-wcirdc-lms-thumb_1735917426
nmdp-mds3_1729518959
soho-2024-enduring-banner-445x250-02-02-02_1727985795
p24011-lms-thumb_1726675197
P23033 LMS Thumb
p24034-obesity-aafp-lms-thumbnail-445x250px_1723738749

On Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
Metastatic Breast Cancer Retreats: Value to the Patient and Your Multidisciplinary Team
Why Your Patients Should Attend a Metastatic Breast Cancer Retreat and the Value it also provides to you and your multi-disciplinary team. This video will demonstrate some of the activities that take place at a MBC retreat and the lessons learned from them.
The Evolution of HCT, Part 3: Donor Availability
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Lessons Learned from Your Patient's Family After Their Loved One Has Died
Our time spent with patients and their families should not end with the transfer of the patient to hospice care. The patient may even resist such a transfer, feeling abandoned by their medical oncology team. Treatment for treatment’s sake is really bad medical care. Doing an effective job of preparing the patient and family for end of life needs to be the ultimate goal as treatments begin to no longer work. Due to having no contact with families after the patients have died results in losing teaching moments for the team that provided her breast cancer treatment. There is great value in incorporating the family’s needs and understanding into the treatment planning process from the beginning so they are better prepared at the end of her life and beyond.
Scroll to Top